No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Johnson & Johnson raised its full-year outlook on Wednesday after second-quarter sales rose 6.6% to $25.31bn, ahead of market expectations, while adjusted earnings increased 4.7% to $2.90 per share.
Innovative Medicine sales grew 7.8% to $16.38bn, driven by strong demand for Tremfya, Darzalex, Carvykti and Caplyta, offsetting declines in older products including Stelara, while MedTech sales rose 4.5% to $8.93bn.
The healthcare group now expects 2026 reported sales of $100.8bn to $101.4bn and adjusted earnings of $11.60 to $11.75 per share, raising the midpoints to $101.1bn and $11.68 respectively.
Chief executive Joaquin Duato said Johnson & Johnson was on track to exceed $100bn of annual revenue for the first time in its 140-year history.
At 1114 EDT (1614 BST), shares in Johonson & Johnson were down 0.6% in New York at $252.32.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.